Procyrion envisions their Aortix device as a less-invasive approach that would keep heart failure patients ambulatory while under treatment.
The small Aortix device, under development now, is being designed for the Class III and IVa heart failure patient.
Even though heart failure affects approximately 6 million Americans, there are surprisingly few device treatments and procedures available for these patients. Left ventricular assist devices (LVADs) have received plenty of attention in recent years for their ability to help severe heart failure patients, but the therapy, which requires invasive surgery, can hold little appeal for people who have less severe heart failure. Yet this same...